research use only
Cat.No.S8327
| Related Targets | JAK TGF-beta/Smad ERK GSK-3 ROCK Hedgehog/Smoothened PKA Secretase STAT Casein Kinase |
|---|---|
| Other Wnt/beta-catenin Inhibitors | ICG-001 IWR-1-endo IWP-2 Isoquercitrin Tegatrabetan (BC-2059) SKL2001 BML-284 (Wnt agonist 1) PRI-724 (Foscenvivint) Salinomycin (from Streptomyces albus) FH535 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| NCI-N87 | Function assay | 5 or 25 μM | 24 h | reduces β-catenin, pan-Ras and p-ERK levels in a concentration-dependent manner | 30965636 | |
| MKN74 cells | Function assay | 5 or 25 μM | 24 h | reduces β-catenin level at a concentration of 25 μM | 30965636 | |
| NCI-H1650 | Function assay | 25 μmol/L | 0, 3, 6, 9, 12 and 24 h | KYA1797K treatment accelerated reduction of β-catenin and pan-Ras levels | 30679620 | |
| NCI-H460 | Function assay | 25 μmol/L | 0, 3, 6, 9, 12 and 24 h | KYA1797K treatment accelerated reduction of β-catenin and pan-Ras levels | 30679620 | |
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 29 mg/mL
(65.53 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 442.51 | Formula | C17H11N2O6S2.K |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1956356-56-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=CC=C1C2=CC=C(O2)C=C3C(=O)N(C(=S)S3)CCC(=O)[O-])[N+](=O)[O-].[K+] | ||
| Targets/IC50/Ki |
Wnt/β-catenin
(in HEK293 cells) 0.75 μM
|
|---|---|
| In vitro |
KYA1797K significantly decreases reporter activities for the Wnt/β-catenin and MAPK/ERK pathways but does not affect the reporter activities of other cancer-related pathways, such as the Notch and TGFβ pathways, thus, this compound selectively regulates the Wnt/β-catenin and Ras/ERK pathways. It enhances the β-catenin binding affinity of endogenous axin, GSK3β and β-TrCP. Interaction between APC and β-catenin is not enhanced by this chemical. It promotes the formation of the β-catenin destruction complex. This compound degrades both β-catenin and Ras in these cells in a dose-dependent manner, cell proliferation is also suppressed by this treatment. It inhibits proliferation of CRC cells mainly via destabilization of β-catenin with additional Ras degradation. This chemical directly targeted axin and modulated conformation of the β-catenin destruction complex.
|
| In vivo |
KYA1797K administration by intraperitoneally injection(i.p.) (25 mg/kg) reduces both weight and volume of the tumor by 70% in mice carrying xenografted tumors from the D-MT cell line that harbors both APC and KRAS mutations. This compound treatment significantly reduces levels of β-catenin and Ras proteins as well as Wnt/β-catenin and Ras signaling target. No change in the weight and no abnormalities in liver tissues of mice treated with this chemical. It significantly reduces the subcellular localization of β-catenin in the nuclei and pan-Ras on the membrane of tumor cells. Thus, this compound has anti-tumor effect.
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.